Nalbuphine ER Tablets + Placebo Tablets
Phase 2/3Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Prurigo Nodularis
Conditions
Prurigo Nodularis
Trial Timeline
Aug 7, 2018 → Feb 24, 2023
NCT ID
NCT03497975About Nalbuphine ER Tablets + Placebo Tablets
Nalbuphine ER Tablets + Placebo Tablets is a phase 2/3 stage product being developed by Trevi Therapeutics for Prurigo Nodularis. The current trial status is completed. This product is registered under clinical trial identifier NCT03497975. Target conditions include Prurigo Nodularis.
What happened to similar drugs?
1 of 7 similar drugs in Prurigo Nodularis were approved
Approved (1) Terminated (0) Active (6)
Hype Score Breakdown
Clinical
15
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03497975 | Phase 2/3 | Completed |
Competing Products
20 competing products in Prurigo Nodularis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Vixarelimab + Placebo | Kiniksa Pharmaceuticals | Phase 2 | 29 |
| Upadacitinib | AbbVie | Approved | 50 |
| Pimecrolimus + Hydrocortisone + Pimecrolimus | Novartis | Phase 2 | 35 |
| Rocatinlimab + Placebo | Amgen | Phase 3 | 44 |
| Abrocitinib | Pfizer | Phase 2 | 35 |
| Dupilumab SAR231893 (REGN668) | Sanofi | Pre-clinical | 33 |
| Dupilumab | Sanofi | Phase 3 | 47 |
| Dupilumab | Sanofi | Pre-clinical | 33 |
| Dupilumab | Sanofi | Pre-clinical | 30 |
| Ruxolitinib Cream 1.5% | Incyte | Phase 1 | 26 |
| Ruxolitinib Cream + Vehicle Cream | Incyte | Phase 3 | 37 |
| INCB054707 + Placebo | Incyte | Phase 2 | 32 |
| Povorcitinib + Placebo | Incyte | Phase 3 | 44 |
| Povorcitinib + Placebo | Incyte | Phase 3 | 44 |
| Ruxolitinib Cream + Vehicle Cream | Incyte | Phase 3 | 37 |
| CDX-0159 + Normal saline | Celldex Therapeutics | Phase 1 | 23 |
| barzolvolimab | Celldex Therapeutics | Phase 2 | 33 |
| nalbuphine HCl ER tablets 90 mg BID + nalbuphine HCl ER tablets 180 mg BID + Placebo tablets BID | Trevi Therapeutics | Phase 2/3 | 32 |
| nalbuphine HCl ER | Trevi Therapeutics | Phase 2/3 | 32 |
| serlopitant + Placebo | Vyne Therapeutics | Phase 2 | 25 |